XTLB
XTL Biopharmaceuticals Ltd ADR
NASDAQ: XTLB · HEALTHCARE · BIOTECHNOLOGY
$2.96
-0.02% today
Updated 2026-07-29
Market cap
$7.27M
P/E ratio
—
P/S ratio
5.77x
EPS (TTM)
$-0.36
Dividend yield
—
52W range
$2 – $10
Volume
0.1M
WallStSmart proprietary scores
24
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D5.3
Quality
C+3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$30.00
+913.68%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity -1.06x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-1.02M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $-459000.00 | $0.00 | $451000.00 | $0.00 | $968000.00 |
| Net income | $-1.35M | $-1782.00 | $-1.03M | $-6.97M | $-6.97M |
| EPS | — | — | — | — | $-0.36 |
| Free cash flow | $-901000.00 | $-707000.00 | $-1.67M | $-1.02M | $-1.02M |
| Profit margin | 293.68% | — | -227.72% | — | — |
Peer comparison
Smart narrative
XTL Biopharmaceuticals Ltd ADR trades at $2.96. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. TTM revenue stands at $968000.00.
Frequently asked questions
What is XTL Biopharmaceuticals Ltd ADR's stock price?
XTL Biopharmaceuticals Ltd ADR (XTLB) trades at $2.96, on a P/S of 5.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is XTL Biopharmaceuticals Ltd ADR overvalued?
XTL Biopharmaceuticals Ltd ADR carries a Smart Value Score of 24/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of XTL Biopharmaceuticals Ltd ADR (XTLB)?
The 12-month analyst consensus target is $30.00, about 913.7% above the current $2.96. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is XTL Biopharmaceuticals Ltd ADR's revenue?
XTL Biopharmaceuticals Ltd ADR's trailing twelve-month revenue is $968000.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.77x
ROE-32.51%
Beta0.55
50D MA$2.61
200D MA$3.17
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—